WO2002015914A1 - Greffe d'un tissu vascularisé - Google Patents

Greffe d'un tissu vascularisé Download PDF

Info

Publication number
WO2002015914A1
WO2002015914A1 PCT/AU2001/001031 AU0101031W WO0215914A1 WO 2002015914 A1 WO2002015914 A1 WO 2002015914A1 AU 0101031 W AU0101031 W AU 0101031W WO 0215914 A1 WO0215914 A1 WO 0215914A1
Authority
WO
WIPO (PCT)
Prior art keywords
tissue
chamber
cells
vascularised
graft
Prior art date
Application number
PCT/AU2001/001031
Other languages
English (en)
Inventor
Wayne A Morrison
Aurora Messina
Kenneth R Knight
Anthony J Penington
Original Assignee
Bernard O'brien Institute Of Microsurgery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPQ9553A external-priority patent/AUPQ955300A0/en
Priority to AU8368701A priority Critical patent/AU8368701A/xx
Priority to AU2001283687A priority patent/AU2001283687B2/en
Priority to KR10-2003-7002551A priority patent/KR20030043937A/ko
Priority to CA2419923A priority patent/CA2419923C/fr
Priority to JP2002520835A priority patent/JP2004505746A/ja
Application filed by Bernard O'brien Institute Of Microsurgery filed Critical Bernard O'brien Institute Of Microsurgery
Priority to NZ524234A priority patent/NZ524234A/en
Priority to US10/362,243 priority patent/US20040052768A1/en
Priority to EP01962458A priority patent/EP1335735A4/fr
Publication of WO2002015914A1 publication Critical patent/WO2002015914A1/fr
Priority to US10/888,436 priority patent/US7998735B2/en
Priority to US11/771,954 priority patent/US20070299508A1/en
Priority to US13/445,685 priority patent/US20120209403A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3625—Vascular tissue, e.g. heart valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0062—General methods for three-dimensional culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/30—Synthetic polymers
    • C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Definitions

  • This invention relates to the fields of tissue engineering and transplantation, and particularly to the generation of vascularised tissue.
  • Tissue engineering utilising homologous starting material offers the prospect of replacing missing or non- functioning body parts with newly created, living tissue. It has the potential to minimise loss of tissue and resultant pain from the donor site experienced in conventional reconstructive surgery or to recreate specialised tissue for which there is no donor site, while obviating the long-term immunosuppression required for heterologous transplantation.
  • tissue engineering One of the major challenges faced in tissue engineering is to create differentiated tissue of the appropriate size and shape. Tissue created without a functional vasculature is strictly limited in size by the constraints of oxygen diffusion; if the tissue is too large it will become necrotic before the host has time to create a new blood vessel supply. Thus there are many advantages in creating new tissue containing a functional vasculature. Additionally, as the new tissue may need to be produced at a site on the body remote from the defect, or on an immunosuppressed carrier animal or in vitro with an extra ⁇ orporeal circulation, the blood supply for the new tissue must be defined, so that it can be brought with the tissue intact to the site of reconstruction.
  • skin flaps a living composite of skin and its underlying fat, is a common technique used to repair tissue defects in reconstructive surgery. Because these flaps must retain their blood supply to remain viable after transplantation, the origin of the flaps is limited to those areas where there is an anatomically recognised blood vessel source.
  • skin flaps can be "pre-fabricated” by implanting short segments of blood vessels into a desired site, and utilising the resultant angiogenesis to vascularise a flap of the desired size and composition. Subsequently this vascularised flap can be transferred by microsurgery to the region of interest. This technique is, however, limited by the availability of donor tissue, and the disfigurement that results at the donor site. In an extension to this technique, Erol and Spira
  • vascularised skin using an AV loop
  • the production of other vascularised tissues suitable for grafting remains elusive.
  • Vascularised adipose tissue for example, is often demanded in reconstructive procedures; however, donor mature adipose tissue is extremely fragile, and will rapidly become ne ⁇ rotic if not immediately re-connected to a functional blood supply.
  • stem cells possess the potential to change their phenotype in response to their environment, and may be able to provide a self-replenishing stem cell population
  • stem cells when the stem cells are injected into mature organs they must interact with an established micro-environment and derive a limited neovasculature from the host organ; when they are systemically injected they become widely dispersed.
  • stem cells In order for stem cells to generate organs, it is expected that they will require an expandable vascular supply to accommodate and service e novo tissue generation.
  • an expandable microenvironment comprising an inert support and/or extracellular matrix is also expected to be required.
  • tissue engineering is a significant advance in the state of the art.
  • the invention provides a method of producing donor vascularised tissue, suitable for transplantation into a recipient animal in need of such treatment, comprising the steps of: a) creating a functional circulation on a vascular pedicle in a donor subject; b) partially or totally enclosing the vascular pedicle within a fabricated chamber; ⁇ ) seeding the chamber with isolated cells or pieces of tissue; d) implanting the chamber containing the vascular pedicle into a host animal at any site where such an anatomical construct can be created; and e) leaving the chamber in the implantation site for a period sufficient to allow the growth of vascularised new tissue.
  • the method comprises the step after step (a) of surrounding the vascular pedicle with added extracellular matrix and/or a mechanical support. In another preferred embodiment, the method comprises a step after step (b) of adding growth factors, drugs, antibodies, inhibitors or other chemicals to the chamber.
  • the chamber is left in the implantation site for at least 4 weeks, more preferably at least 6 weeks.
  • the vascularised tissue may be grown in vivo or in vitro, or may be in situ in the host.
  • the chamber is implanted in the donor body, beneath the skin, although it is not limited to subcutaneous insertion. While externalization of the chamber during tissue/organ growth is theoretically possible, the high risk of infection makes this a rarely used alternative.
  • the term "donor subject” is taken to mean an animal, especially a mammal and most especially a human, in which the donor vascularised tissue is created.
  • the term "recipient animal” is taken to mean an animal, especially a mammal and most especially a human, that receives the donor vascularised tissue graft.
  • the donor subject is preferably a mammal, and may be a human or a non-human animal.
  • Preferred mammals include rodents, felines, canines, hoofed mammals such as horses, cows, sheep and goats, pigs, and primates.
  • the donor subject and recipient are human.
  • vascular pedicle is an artificial or naturally occurring arrangement of blood vessels or vessel replacements that comprises an artery taking blood to the site of the construct and a vein carrying it away.
  • the vascular pedicle comprises an arterio-venous (AV) loop or shunt.
  • AV arterio-venous
  • the artery is either joined directly to the vein or connected via a graft of a similar diameter so that there is no impediment to blood flow (for example as illustrated in Figure
  • the artery and vein are both ligated and blood flow is via microscopic connections between the two (for example as illustrated in Figure 3) .
  • the artery and vein are in a "flow through" configuration with the blood vessels entering at one end of a semi-closed chamber and exiting at the opposite side (for example as illustrated in Figure 4) .
  • the term "functional circulation” as used herein describes a circulation that has at least one of the following properties: the vessels making up the circulation are patent, the vessels are capable of sustaining blood or blood-substitute flowing through them, the vessels are capable of supplying nutrients and/or oxygen to nearby tissue and the vessels are capable of forming new blood vessels by budding.
  • the chamber may also be supplied with added extracellular matrix, for example matrix deposited by cells in situ, reconstituted basement membrane preparations such as MatrigelTM or laminin (mouse origin), AmgelTM, HumatrixTM, or laminin (all of human origin) with or without matrix metalloproteinase inhibitors, polylactic-polyglycolic acid variants (PLGA) , fibrin or plasma glue (autologous or heterologous) with or without fibrinolysis inhibitors, or native collagen (autologous or heterologous) with or without collagenase inhibitors .
  • matrix deposited by cells in situ reconstituted basement membrane preparations such as MatrigelTM or laminin (mouse origin), AmgelTM, HumatrixTM, or laminin (all of human origin) with or without matrix metalloproteinase inhibitors, polylactic-polyglycolic acid variants (PLGA) , fibrin or plasma glue (autologous or heterologous) with or without fibrinolysis inhibitors, or native
  • extracellular matrix-like polylactic-polyglycolic acid sponges, DexonTM sponges, or sea sponges are added to the chamber.
  • Combinations of matrices, such as PLGA sponges coated with one or more other matrix- forming components such as fibrin, laminin, fibronectin, collagen, low molecular weight hyaluronan and vitronectin are other preferred options.
  • Freeze dried segments of tissues such as muscle or organs such as liver may be used as sources of matrix and growth factors.
  • the segments of tissues or organs are taken from the same species as the donor subject, and most preferably taken from the donor individual .
  • the donor subject is the same individual as the recipient animal, i.e.
  • the graft is autologous.
  • the donor subject may be an immunocompromised animal, such as an athymic mouse or pig, and the recipient may then be a different individual, i.e. the graft is heterologous.
  • Other permutations and combinations of these procedures may include the use of either autologous or immunocompromised blood vessels, cells, tissue segments or growth factors implanted back into either the original donor or a different recipient individual. Whether or not the "maturity" of the graft confers immunoprotection on a heterologous graft is another variant that can be tested using routine techniques.
  • the tissue or cells used in the chamber may be supplemented with additional growth factors selected from the group consisting of "homing" factors to attract stem cells from the circulation, exogenous growth factors such as ⁇ -Fibroblast Growth Factor (OCFGF or (XFGF-1) , ⁇ -Fibroblast Growth Factor ( ⁇ FGF-1 or ⁇ FGF-2), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF-A,B,C,D or E) ,
  • additional growth factors selected from the group consisting of "homing" factors to attract stem cells from the circulation, exogenous growth factors such as ⁇ -Fibroblast Growth Factor (OCFGF or (XFGF-1) , ⁇ -Fibroblast Growth Factor ( ⁇ FGF-1 or ⁇ FGF-2), Platelet-Derived Growth Factor (PDGF), Vascular Endothelial Growth Factor (VEGF-A,B,C,D or E) ,
  • Angiopoietin-1 and -2 Insulin-like Growth Factor (IGF-1), Bone Morphogenic Protein (BMP-2 and -7), Transforming Growth Fa ⁇ tor- ⁇ and - ⁇ (TGF- ⁇ , TGF- ⁇ ), Epidermal Growth Factor (EGF), Connective Tissue Growth Factor (CTGF) , Hepatocyte Growth Factor (HGF) , Human Growth Hormone (HGH) , Keratinocyte Growth Factor (KGF) , Tumour Necrosis Factor- ⁇ (TNF- ) , Leukemia Inhibitory Factor (LIF) , Nerve Growth Factor (NGF) , Granulo ⁇ yte Macrophage Colony Stimulating Factor (GM-CSF) and other factors such as 3-isobutyl-l-methylxanthine (IBMX), insulin, indomethacin, dexamethasone, hyaluronan hexasaccharide, the PPAR- ⁇
  • Antibodies, agonists or antagonists to some of these growth factors or inhibitors of the chemical mediators can also be used to influence the type of tissue formed and the rate of its formation.
  • the person skilled in the art will readily be able to test which growth factor(s), anti-growth factor antibodies, or inhibitors, or combination thereof, are most suitable for any given situation.
  • the chamber may be used with autologous or heterologous cells, such as myoblasts transfected with Myo-D to promote formation of the skeletal muscle phenotype, stem cells with appropriate differentiation factors, keratinocytes seeded to produce thin skin constructs for face and neck reconstruction, etc.
  • the chamber may also comprise isografted or autologous cells selected from the group consisting.
  • myoblasts myoblasts, fibroblasts, pre-adipocytes and adipocytes, cardiomyocytes, keratinocytes, endothelial cells, smooth muscle cells, chondrocytes, pericytes, bone marrow-derived stromal precursor cells, embryonic, mesenchymal or haematopoietic stem cells, Schwann cells and other cells of the peripheral and central nervous system, olfactory cells, hepatocytes and other liver cells, esangial and other kidney cells, pancreatic islet ⁇ -cells and ductal cells, thyroid cells and cells of other endocrine organs.
  • the chamber may be used with additional autologous or isografted portions of skeletal or cardiac muscle, pancreas, liver, epididymal and other subcutaneous fat, nerves (peripheral, blood vessel-associated, etc), kidney, bowel, ovary, uterus, testis, olfactory tissue or glandular tissue from endocrine organs.
  • pieces of tissue shall be taken to encompass any aggregates of cells, with or without additional extracellular material such as extracellular matrix, either taken directly from an animal or produced as a result of manipulation of cells in tissue culture, or a combination of the two.
  • tissue segments may be rendered ischaemic, cell-depleted or necrotic in order to provide cues or signals to the surviving stem cells and other cells which may influence tissue development.
  • the vascularised tissue is enabled to differentiate.
  • stem cells together with appropriate extracellular matrix and growth factor supplements, are supplied to the chamber in order to produce vascularised, differentiated tissues or organs.
  • Suitable pluripotent stem cells can be derived from: a) blood; b) bone marrow; c) specific organs or tissues, including mesenchymal stem cells; d) cultured cells, which may be transfected or differentiated; or e) placental stem cell banks.
  • sources such as bone marrow, ischaemic skeletal muscle, and subcutaneous adipose tissue.
  • Other potential sources of pluripotent stem cells are blood, especially from a fetus or newborn individual but also from an adult, and human placenta.
  • a number of stem cell banks such as bone marrow or cord blood banks are already established. Human embryos are a potential clinical source of stem cells, although legal and ethical issues precludes their use at present in some countries.
  • differentiated cells produced depends on the origin of the stem cells, the local environment, the presence of tissue-specific growth or dif erentiation factors, and other factors. For example, unexpectedly we have observed that ischaemic skeletal muscle placed in the chamber with an AV loop differentiates into predominantly adipose tissue after 4-6 weeks. Without wishing to be limited by any proposed mechanism, we believe that in this case, mesenchymal stem cells in the muscle, together with the stimulus of acidic ischaemic metabolites, are potentially responsible for this differentiation.
  • the chief advantage of using stem cells is their huge proliferative capacity, so that relatively few cells are required to generate a large colony for seeding the chamber and the AV loop.
  • the vascular pedicle such as an AV loop comprises an artery joined to a venous graft, which is in turn joined to a vein.
  • the AV loop comprises an artery joined to a vein directly, or the AV loop comprises an artery joined sequentially to a venous graft, an arterial graft, and a vein.
  • a pedicle comprising the ligated stumps of an artery and vein (eg. the femoral vein) placed side by side in the chamber can be used as the blood vessel supply.
  • the AV loop vessels flow in and out of the chamber from the same edge.
  • the artery and vein are neither divided nor formed into a shunt, but instead flow in one side of the chamber and out the opposite side (see, for example. Figure 4) .
  • the artery and vein are divided and placed side by side in the chamber, the vessels both entering from the same edge; this is illustrated in Figure
  • the graft portion of the AV loop may be derived from the host or from a separate donor. Cold-stored or prefabricated vessels may also be used.
  • an additional step involves the incorporation of a nerve stump, so that tissue in the chamber may become innervated.
  • Skeletal muscle for example, requires proximity to a nerve for its maintenance and maturity; otherwise it will atrophy.
  • the chamber containing the vascular pedicle has a defined internal dimension.
  • the internal dimensions, volume, and shape may be varied in order to influence the volume and shape of the new tissue being produced.
  • the internal volume of the chamber may be increased, without altering the external size of the chamber, by providing thinner walls;
  • the shape of the chamber may be constructed to resemble that of the target organ or body part, such as an ear, nose, breast, pancreas, liver, kidney, finger or other joint;
  • the degree of permeability of the walls of the chamber may be varied;
  • the chamber may include a semi-permeable membrane component to allow selective perfusion of molecules into and out of the chamber, or a plurality of perforations may be placed in the walls of the chamber to allow an increased flow of metabolites and metabolic by-products, growth factors and other factors that influence cell survival, growth and differentiation between the inside and outside of the chamber.
  • the size, shape and number of the perforations may be selected according to the size of the donor vascularised tissue and the requirement to keep the contents of the chamber isolated from direct contact with the implantation site.
  • a semi-permeable component may be placed within the chamber in order to isolate "feeder" cells from immune reactions .
  • populations of fibroblasts or other cells can be transfected, then used as a source of the transfected gene product (s) within the chamber.
  • This construct is placed within a semi-permeable pocket out of contact with the host's immune system. Drug delivery is used to switch the transfected gene on or off. These cells will survive by diffusion as long as they receive adequate nutrients, but will eventually die.
  • the surface chemistry of the chamber walls may be modified, in order to modify the interaction between the tissue and the chamber wall, to provide a stimulus for differentiation or to incorporate or be coated with a gel, such as alginate, which mediates the slow release of a chemical or biological agent to create a gradient.
  • a gel such as alginate
  • the degree of internal support within the chamber may be varied, eg there may be: a) no support; b) a solid support which directs, encourages or inhibits the growth of the new tissue, or excludes new tissue, or is incorporated into the new tissue; c) a transient support based on resorbable materials; d) a porous supporting material which supports cell and vascular ingrowth, providing a skeleton over which the new tissue can be generated, eg sponge-like materials such as blown PTF ⁇ materials, PLGA sponges of variable composition and porosity, etc; e) a support formed from materials which direct tissue differentiation, such as hydroxyapatite or demineralised, granulated bone.
  • the exterior surface of the chamber bears a means by which the chamber can be attached and/or immobilised to the desired region of the body.
  • the invention provides a vascularised tissue graft, ie. the contents of the chamber, comprising differentiated tissue or an organ with a mature vascular supply.
  • the graft predominantly comprises tissue selected from the group consisting of adipose tissue, cartilage, bone, skeletal muscle, cardiac muscle, loose connective tissue, ligament, tendon, kidney, liver, neural tissue, bowel, endocrine and glandular tissue. More preferably the graft predominantly comprises vascularised adipose tissue, skeletal muscle, cartilage or bone tissue or tissue comprising pancreatic islet and/or ductal cells, kidney cells or liver cells.
  • the invention provides a method of repairing a tissue deficit, comprising the step of implanting a tissue chamber according to the invention into a patient in need of such treatment, in which: a) the tissue or "organ" graft is formed according to the methods of the invention, and; b) retained for sufficient time to mature ie. to achieve the desired size, vascularity and degree of differentiation, and; c) transferred to the desired recipient site; and d) the blood vessels of the graft are microsurgically anastomosed to a local artery and vein.
  • tissue deficit will be taken to comprise a shortfall in the normal volume, structure or function of a tissue in the recipient.
  • a tissue may be selected from, but is not limited to superficial tissues such as skin and/or underlying fat, muscle, cartilage, bone or other structural or supporting elements of the body, or all or part of an organ.
  • the augmentation of otherwise normal tissues for cosmetic purposes, such as forms of breast augmentation, is also provided by the invention.
  • a person skilled in the art will readily recognise that such a tissue deficit may be a result of trauma, surgical or other therapeutic intervention, or may be congenitally acquired.
  • the invention provides a method of providing a subject with a gene product, comprising the steps of: a) constructing a tissue chamber according to the invention to create vascularised tissue from a patient in need of such therapy; b) removing the chamber with its vascularised tissue and culturing the chamber assembly in vitro; c) transforming cells of the tissue in the chamber with a desired gene; and d) implanting the chamber or the contents minus its chamber into the patient .
  • the timing of the genetic transformation of the tissue- producing cells can be varied to suit the circumstances, for example the cells may be transformed at the time of setting up the chamber construct, during the incubation, or immediately prior to transplantation.
  • gene products can take several forms.
  • One example is the transfection of myoblasts with the Myo-D gene to create tissue with a normal skeletal muscle phenotype. Such transfected cells may then be seeded into the desired chamber, matrix and AV loop to generate vascularised skeletal muscle. This may have implications for the treatment of muscular dystrophy and other genetically inherited muscle diseases.
  • a second example is the transfection of pancreatic islet cells with a "healthy" phenotype and their seeding into the chamber. This approach may prove to be useful in the treatment of diabetic patients.
  • cells are transfected with a growth factor gene or an angiogenesis- promoting gene, such as PDGF, bFGF or VEGF, prior to seeding them into the chamber together with the AV loop and selected matrix.
  • a growth factor gene or an angiogenesis- promoting gene such as PDGF, bFGF or VEGF
  • This continuous production of growth factor is designed to speed up the rate of development of, and the rate of new blood vessel formation within, the new tissue/organ.
  • the invention provides a model system for vascularised tissue, comprising a tissue chamber containing a vascular pedicle of the invention and optionally an extracellular matrix, operably connected to an extracorporeal circulation apparatus and renal dialysis filter.
  • the extracorporeal circulation apparatus and renal dialysis filter may be of any suitable conventional type.
  • the cells forming the tissue in the chamber are optionally transformed so as to express a heterologous gene.
  • This model system may be used for culturing, recruiting, growing and studying the behaviour of stem cells or tissue containing precursor cells, either in vitro or in vivo. Because of the ability to alter the environment of the chamber with added growth, differentiation and chemical factors, it is possible to produce a wide variety of tissues and organs by this process.
  • tissue in the chamber may, for example, be manipulated by a) gene transfection, b) administration a local drug or other "factor", or c) creating a site of circulatory stem cell homing.
  • tissue and exudate in the chamber may readily be harvested to monitor progress of tissue growth and development. Above all, it is the ability to grow and transplant new vascularised, differentiated tissues or organoids that sets this invention apart from others.
  • Figure 1 illustrates how the femoral artery and vein are anastomosed microsurgically to a vein graft of similar diameter to form a loop (shunt) .
  • the AV loop is placed as shown in a plastic chamber (made of polycarbonate or poly-L-lactic acid, etc), the lid secured, and the chamber optionally filled with an extracellular matrix with or without added cells or growth factors.
  • the chamber is anchored in position relative to the surrounding tissue by means of stay sutures through external holes.
  • Figure 2 shows a configuration similar to Figure 1, except that the lid of the chamber is dome-shaped and the edges of the chamber are more rounded to minimise wound breakdown.
  • Figure 3 depicts an example of the thin-walled chamber used for the pedicle model.
  • an artery and a vein are ligated distally and placed adjacent to each other. Microscopic connections between the artery and vein become established, and form an AV loop in a similar manner to that shown in Figures 1 and 2.
  • Figure 4 shows a model chamber similar to that in Figure 3, but with exit holes for the blood vessels at either end of the chamber. This allows an undivided, dissected length of blood vessels, placed side by side, and in some variants surrounded with extracellular matrix, to form new tissue.
  • Figure 5 shows the inner aspect of an AV loop- containing chamber, 7 days after insertion. Fluorescence microscopy shows labelled fibroblasts evenly distributed across the chamber surface, magnification x 160 (see Example 2) .
  • Figure 6 shows a reconstructed "breast" on a male rabbit, constructed using a vascularised, tissue-engineered fat and connective tissue flap created at a remote site (the groin region) in the same rabbit (see Example 10) .
  • a custom-made polycarbonate chamber was prepared. It has a top and a bottom, and when the two halves are sealed together the internal volume is 0.45-0.50 ml.
  • the general construction of the chamber is illustrated in Figure 1.
  • the basic chamber for use in rats is made of polycarbonate.
  • the chamber is made of polylactic acid or PLGA.
  • the chamber is in the shape of a cylinder of external dimensions 14 mm diameter and 4 mm high, with a saw cut on one side to create an opening for the blood vessel entry and exit.
  • Another variant has cut openings on opposite sides of the chamber to allow blood vessels to flow in one side and out the other.
  • the chamber has a base and a removable lid.
  • the base has holes to allow anchoring of the chamber to subcutaneous tissue.
  • the internal volume is approximately 0.45-0.50 ml.
  • the internal volume of this basic chamber can be varied, maintaining the same external volume, by using thinner walls, which may even be as thin as a standard plastic film used in food storage.
  • An alternative design is in the shape of a "dome" with more rounded edges, as shown in Figure 2.
  • Other variants include an elongated, flattened cigar shape as shown in Figure 3 which fits readily into the subcutaneous space in the groin.
  • the shape of the chamber may be designed to mimic the shape or contours of a particular body part, for example a human finger joint or thumb, human ear, human nose, human breast, etc.
  • the size of the chamber can be scaled up or down to suit the size of the host.
  • the internal volume for a chamber to be used in a mouse may be approximately 0.1-0.2 ml, in a rabbit 10-12 ml, but in a human can be up to approximately 100-200 ml.
  • the chamber may optionally be sealed.
  • the opening allows limited contact with the surrounding tissue and total uninterrupted contact with the blood supply.
  • the opening is engineered to allow just enough space for the ingoing artery and outflowing vein without crushing the blood vessels.
  • the vessel ports are sealed, for example with fibrin glue, to avoid contact of the developing graft with surrounding tissue.
  • the surface of the polycarbonate chamber can be left in its native hydrophobic state, or can be rendered relatively more hydrophilic by the use of polylactic acid or the pre- treatment of polycarbonate with a thin film of poly-L-lysine.
  • the surface of the chamber comprises, a plurality of perforations, allowing increased contact with growth factors in the surrounding tissue.
  • the size and shape of the perforations may be tailored to optimise the passage of the desired factors, while minimizing or preventing the passage of cells.
  • chambers are made of glass or Pyrex they can be coated with silicone.
  • the chamber design should ideally fit comfortably into the recipient site, and should be of a rounded shape and of a sufficiently small size to avoid wound break down.
  • the internal contents of the chamber are sufficiently large to accommodate an osmotic pump (eg. an AlzetTM osmotic mini pump) to deliver drugs, growth factors, antibodies, inhibitors or other chemicals at a controlled rate.
  • an osmotic pump eg. an AlzetTM osmotic mini pump
  • the osmotic pump may be placed subcutaneously outside the chamber with a plastic tube leading from the pump placed inside the chamber, eg. at the centre of the AV loop.
  • This vein graft (approximately 1.5 - 3 cm long; usually 2 cm) was interposed between the recipient right femoral vein and artery at the level of the superficial epigastric artery by microsurgical techniques using 10-0 sutures.
  • the shunt was placed into the chamber, the lid closed and the construct sutured to the groin musculature with the aid of small holes on the base of the chamber.
  • An adipose layer was placed over the chamber and the wound closed with 4-0 silk sutures.
  • the growth chambers with the AV shunts were harvested at either 2, 4 or 12 weeks post implantation. Assessment of Vascularisation and Tissue Creation
  • the chamber was opened, and the vessels cleaned and tested for patency.
  • the vessels were tied off with a 5-0 silk suture at the entrance of the chamber and the flap harvested.
  • the flap was perfused, via the aorta, with India ink prior to harvest (details below) .
  • the flaps were assessed for volume and weight and placed in buffered 10% formal saline (BFS) for histological examination.
  • BFS formal saline
  • the animals were sacrificed with an intracardiac dose of sodium pentabarbitone ( ⁇ 3 ml of 250 mg/ml solution) at the completion of the exploration.
  • the tissue in the chamber was removed and its wet weight and volume recorded.
  • the volume of the tissue was assessed by a standard water displacement technique.
  • the tissue was suspended by a 5-0 silk suture in a container of normal saline which had been zeroed previously on a digital balance. Care was taken not to touch the container with the specimen.
  • the weight recorded was the volume of the tissue specimen (with a density equal to that of normal saline, 1.00 g/ml) .
  • the mass of the specimen was assessed at the same time on the same digital scale by allowing the tissue to rest on the base of the container, and recording the weight.
  • India ink per fusion In order to perfuse the flaps with India ink, the abdomen was opened via a midline incision.
  • the intestines were gently retracted to the periphery and the periaortic fat stripped away.
  • the proximal aorta and inferior vena cava were ligated.
  • the aorta was cannulated with a 22-gauge angiocatheter which was secured with a distal suture around the angiocatheter and aorta.
  • a venotomy was carried out in the inferior vena cava.
  • the aorta was perfused with 10 ml of heparinised saline to flush out the retained blood, the animal was sacrificed with intracardiac sodium pentabarbi one (3 ml of a 250 g/ml solution) , the aorta infused with 3 ml buffered 10% formol saline (BFS) and then with 5 ml India ink in 10% gelatin. The flap vessels were then tied off. Tissue from the chamber was removed, fixed in BFS, cleared in cedar wood oil and the pattern of vessels visualised microscopically using transmitted light and image analysis (Video ProTM imaging) . Histology- Specimens were fixed in buffered formol saline and embedded in paraffin. Sections (5 ⁇ m) were cut and stained with either haematoxylin & eosin (H & E) or Masson's Trichrome.
  • Example 1 Creation of Vascularised Tissue in Chambers with an AV loop
  • the average mass of the AV shunt vessels prior to insertion was 0.020 g (exsanguinated) and 0.039 g (when full of blood) .
  • Two weeks after insertion the AV shunt and its surrounding tissue weighed 0.18 ⁇ 0.03 g.
  • the mass increased progressively being 0.24 ⁇ 0.04 g at 4 weeks and 0.28 ⁇ 0.04 g at 12 weeks.
  • the volume of the new tissue closely paralleled its weight.
  • the increase in weight but not volume between 2 and 12 weeks was statistically significant (P ⁇ 0.05, ANOVA/Dunnett' s test) .
  • the AV loop was surrounded by a mass of coagulated exudate containing varying amounts of clotted blood.
  • the mass of tissue around the loop was larger and firmer, especially in its central part.
  • the newly formed tissue surrounding the loop had increased still further in volume and now filled approximately two-thirds of the chamber.
  • the surface coagulum was no longer visible, and the whole mass had a uniformly firm consistency.
  • the AV shunt was surrounded by a cuff of newly-formed connective tissue composed of fibroblasts, thin collagen fibres and vascular sprouts, arranged roughly vertical to the shunt.
  • Inflammatory cells both neutrophils and macrophages, were present in moderate numbers in the outer part of the newly formed tissue and in the surrounding mass of coagulated inflammatory exudate.
  • branches of newly-formed blood vessels arising from the venous lumen of the AV shunt could be identified.
  • the newly formed tissue was more mature.
  • the zone closest to the AVS contained a dense plexus of newly formed vessels embedded in mature collagenous stro a. Outside this layer was a less mature zone similar to the newly formed tissue in the 2 weeks specimens. Most of the surrounding coagulum was no longer visible, and only small numbers of inflammatory cells were present in the newly formed tissue. As at 2 weeks, communications between the AV shunt and the newly formed vessels were visible in some sections.
  • the newly formed tissue had matured still further, and consisted of dense collagenous connective tissue with fibroblasts aligned parallel to the outer margin of the AV shunt. There was no apparent decrease in vascularity and newly formed vessels formed a dense plexus throughout the connective tissue. Few inflammatory cells were visible.
  • the specimens which were injected with India ink gave a clearer picture of the extent and density of the newly formed vasculature. In most specimens almost all vessels contained carbon in their lumen, indicating that they communicated with the AV shunt.
  • newly formed tissue must be stable and capable of retaining its shape. The tissue formed around an AV loop has both these characteristics. At 2 weeks the mass within the chamber is soft and readily deformed.
  • Example 2 Chambers with rat dermal fibroblasts
  • Rat skin was harvested in a 6 cm by 4 cm ellipse from the groin area of an inbred Sprague-Dawley rat line (Monash University Animal Services, Clayton, Victoria, Australia) .
  • the inbred line comprised animals resulting from at least 20 generations of brother-sister matings.
  • the epidermis was trimmed off. Segments of der is were cut into 2mm by 2mm squares and 10 pieces were placed onto a sterile Petri dish and attached to the base using rat plasma "glue" .
  • This glue was made by the addition of 2 ml of rat plasma, prepared from Sprague Dawley rats, to 0.3 ml of 2% calcium chloride. The glue was allowed to set for 10 min at 37° C. Complete culture medium, comprising Dulbecco's Modification of Eagle's Medium (DMEM), 10% fetal calf serum, penicillin and streptomycin and glutamine, was added to the culture dish. The skin segments were left undisturbed for 7 days, then the medium was changed. There was considerable outgrowth of fibroblasts by 10 days, at which time the skin segments were removed. The fibroblasts were subcultured twice at weekly intervals, each time growing the cells in 75 cm 2 and 175 cm 2 culture flasks respectively.
  • DMEM Dulbecco's Modification
  • the fibroblasts were labelled with two fluorescent labels, bisbenzamide (BB) and carboxyfluorescein diacetate
  • CFDA phosphate buffered saline
  • CFDA persists in the cytoplasm of cultured cells and survives the division of cells into daughter cells. CFDA fluoresces maximally at 513 nm; BB fluoresces maximally at >430nm. Labelled cells were protected from light, in an effort to maintain maximal fluorescence.
  • the fibroblast culture flasks Prior to the addition of cells to the chambers, the fibroblast culture flasks were trypsinized and the trypsin neutralized. 10 ⁇ l of suspended cells were counted using a hemocytometer, and 0.05% Evan's blue dye in a 1:10 ratio. The solution was centrifuged and the resulting cell pellet suspended in an appropriate volume of bovine collagen solution to yield a cell concentration of 1 million cells/ml.
  • Rat tail tendon collagen (RTTC)
  • the tendons from six rat tails were harvested and diced into 2x2x2 mm cubes (yield approximately lOg) .
  • Four hundred ml of cold 0.5 M acetic acid was added and the mixture homogenized and left stirring at 4°C for 24 h.
  • the homgenate was centrifuged (3000 rpm x 20 min) and the supernatant harvested. This extraction procedure was repeated twice with further additions of 300 ml of cold 0.5 M acetic acid.
  • To the pooled extracts a solution of 5 M NaCl was added slowly, with magnetic stirring at 4°C, until the final concentration of salt was approximately 0.7 M (100 ml of 5M NaCl added to every 600 ml of extract) .
  • each half of the chamber was then examined, using a x 10 ocular, to determine the number of Evan's blue-stained and fluorescent cells in 7 randomly selected microscopic fields. The number of labelled cells in 7 random fields on the surface of the AV shunt was then determined.
  • the shunt and surrounding tissue covered approximately 20% of the surface of the chamber; by 7 days this had increased to approximately 30%.
  • the overall density of cells in the chamber containing an AV shunt was calculated by summation of the density of cells on the surface of the chamber and 20% (2 days) or 30% (7 days) of the labelled cells on the surface of the AV shunt.
  • Paired t-tests were used to compare number of cells per grid in the control and experimental chambers and the preoperative number of cells per grid using Microsoft ExcelTM and Graph Pad PrismTM software (San Diego, CA, USA) .
  • the shunt and surrounding tissue was fixed in 10% formol saline, embedded in methacrylate and thin sections prepared and stained with either haematoxylin and eosin or Masson's trichrome.
  • the AV loop was patent in every chamber.
  • the AV shunt covered approximately 20% of the surface of the chamber. By 7 days the area covered by the AV shunt and new tissue arising from it had increased to approximately 30%.
  • the 2 day mean weight of the shunt was 0.12 ⁇ 0.017 g and the mean volume was 0.12 ⁇ 0.014 ml.
  • the mean weight had risen to 0.23 ⁇ 0.018 g and the mean volume to 0.21 ⁇ 0.015 ml.
  • Density of labelled cells (mean number/grid) in empty and AV shunt containing chambers, pre-operatively and 2 and 7 days after insertion.
  • the density of the cells in empty chambers did not differ significantly from the density 2 days after insertion.
  • Evan's blue staining showed that in all chambers examined virtually all labelled fibroblasts were viable, with less than 1% of cells taking up the Evan's blue dye.
  • Example 3 Differentiation of stem cells in implanted tissue chambers Skeletal muscle, pancreas, fat, liver and kidney were aseptically removed from four inbred Sprague-Dawley rats. They were chopped into 1 mm cubes and placed in a tissue culture- grade petri-dish (15-20 pieces each 7 cm 2 of culture surface) containing 1-2 ml of complete serum-free DMEM. They were then incubated for a minimum of 24 h and up to 3 days. At the appropriate time 4-6 pieces of tissue were adhered in a plasma clot to each side of a chamber bf the type described in Exam le 2. The chamber was then seeded with the AV loop and closed. The proximal end of a femoral nerve was placed inside one half of the chambers containing skeletal muscle explants. After 4-6 weeks the rats were sacrificed and the chambers examined.
  • the contents of chambers with tissue explants differed from the contents of chambers without tissue explants, in that they contained new and different cell phenotypes. In all cases most of the necrotic tissue explants had been replaced by clumps of new cells.
  • the chambers seeded with portions of pancreatic tissue had a large population of well-demarcated large ovoid eosinophilic cells, many giant cells and other smaller cells.
  • stem cell population, either attracted into the chamber from a circulating stem cell source by the necrotic tissue explants, or contained within the tissue explants, has given rise to the new tissue.
  • tissue was used, in comparison to the large amount required to isolate stem cells, and our results indicate that this is a novel and efficient method to obtain stem cells.
  • the stem cells may have differed with respect to their degree of commitment to a particular tissue type, or else they may have responded to cues expressed by the unique microenvironment of the different explants, to proliferate and differentiate into the different cell types observed.
  • the generation of encapsulated adipose tissue described here is, to our knowledge the first time that such a neo- organoid has been grown de novo on its own artery and vein.
  • a detailed study of the spatio-temporal and dynamic changes in the chamber and the mechanism by which these events give rise to the neo-organ may also have applications in defining in vivo stem cell availability and behavior.
  • the chamber model is superior to any other in vivo model available so far, since it enables a wide variety of manipulations of the chamber contents and environment and stem cell sources. Furthermore, it enables a study of stem cells in a naive environment without the influences of other nearby tissues, as opposed to the growth of stem cells in an established tissue.
  • a stem cell population can successfully seed the chamber; b) the chamber model supports the plasticity of stem cells; c) a satisfactory, appropriate and adequate neovascularisation develops with, integrates and supports the tissue construct; d) the constructs are not overcome by fibroblastic ingrowth; and e) the constructs are not overcome by inflammatory cells.
  • a pilot study was devised to determine if there was any initial loss of Matrigel during 20 minutes of contact with the AV loop. Based on the results of the pilot study, time periods of 2, 4 and 8 weeks were chosen. At the 4 week time period a further comparison was done with growth factor-reduced Matrigel. Six male Sprague-Dawley rats were used per group, each weighing between 220 and 280 g. The arterio-venous loop procedure was carried out as described in the Experimental Procedures .
  • Matrigel (Collaborative Research Inc, Bedford, MA, USA) was divided into in sterile 10 ml aliquots at an approximate concentration of 12 mg/ml in DMEM containing 10 ⁇ g/ l of
  • GFR Growth factor reduced
  • Matrigel Under sterile conditions, 0.5 ml of Matrigel was added to each sterile chamber at room temperature where it gelled rapidly (within 15 seconds) . The chamber with matrigel was then placed in position in the rat's right groin. The Matrigel is gelatinous at room temperature, enabling immersion of the loop within it. In the pilot study the AV loop was made and immersed in the Matrigel for 20 minutes before implantation, to determine whether there was any initial loss of Matrigel from • the chamber due to liquefaction of the matrix.
  • the new tissue flaps were harvested at 2, 4 and 8 week periods.
  • the flaps were harvested at the above time periods, and assessed for weight, volume and histology.
  • Statistical analysis was carried out comparing the 2, 4 and 8 week groups with each other and the AV loop alone (See Example 1) .
  • a further comparison was done at 4 weeks between Matrigel, GFR Matrigel and the AV loop alone at 4 weeks .
  • Matrigel proved easy to manipulate in vitro. There was minimal loss of Matrigel after 20 minutes of contact with the AV loop.
  • Microfil injection demonstrated good filling of flap vessels, including the advancing microvessels . This appearance was not apparent at 8 weeks, when the flaps were smaller and with a more regular smooth surface. At 8 weeks there was only residual fluid in the chamber, and no viscous Matrigel was visible.
  • the vessels had matured into arterioles and venules, with larger branching vessels arising from the loop and smaller branches at the periphery. There was still some unincorporated Matrigel and small amounts of haemorrhage. The unincorporated Matrigel contained sparse fibroblasts and the occasional vessel. The general impression was of a maturing but still growing flap with good vessel formation.
  • the flap tissue appeared more mature, with denser collagen and larger vessels nearer the loop. It was less cellular with less vessels . A capsule had started to form around the generated tissue, and there was residual Matrigel remaining within the flap.
  • the GFR Matrigel flaps appeared to be more mature, with larger vessels in the centre and less active angiogenesis at the periphery. There was evidence of early capsule formation and in some specimens more inflammatory cells were present. At all time courses Microfil injection demonstrated good vascular connection between the loop and the flap vessels.
  • PLGA prepared by the salt- leached method.
  • a PLGA insert for the tissue chamber was constructed using a particulate leaching method as described by Patrick et al (1999) .
  • PLGA is dissolved in chloroform and mixed with NaCl. After evaporation of the chloroform the resulting scaffold is machined to the desired shape.
  • the salt was then leached from it leaving interconnected pores.
  • the pore size is a reflection of the size of the salt particle used. In this experiment pores of 300-400 ⁇ and a porosity of 84% were made.
  • the PLGA was machined in two parts so as to fit inside the polycarbonate chamber.
  • the lower part comprised a base plate containing a groove for the loop and the upper part comprised a flat disc to cover the loop and base plate.
  • the PLGA discs were 1.4 mm in diameter by 2.5 mm thick.
  • the PLGA was sterilised and pre-wetted by soaking in 100% alcohol for 30 minutes on a mechanical stirrer then subjecting them to three
  • the arteriovenous loop was prepared as described above, and placed into the base plate of PLGA sitting in the chamber. The superior disc was placed on top and the chamber closed.
  • Each group of rats contained 6 male Sprague-Dawley rats, with each rat weighing between 220 and 280 grams.
  • the chambers were harvested at either 2 or 4 weeks. Weight, volume and histology were assessed at both time periods. Immunohistochemical staining of flap sections for ⁇ -actin was carried out to detect myofibroblasts. In each group, one chamber was excluded, one due to infection and the other to dehiscence, leaving 5 rats in each group.
  • the vessels had almost entirely vascularised the construct, with some uninvolved PLGA at the tip.
  • the capsule had begun to form proximally near the portal.
  • the construct was entirely encapsulated, and had shrunk and retracted, withdrawing from the sides of the chamber. Micro-fill injection demonstrated the extent of vessel penetration.
  • the 2 week flap weight was 0.43 + 0.05g and the volume 0.38 + 0.04 ml.
  • the 4 week flap weight was 0.33 g + 0.04 g and the volume 0.29 ml + 0.04 ml.
  • a comparison between the 2 and 4 week groups showed a reduction in flap size between 2 and 4 weeks. This result was not statistically significant. Further comparison with other experiments was not possible due to the presence of PLGA retained within the flap, which skewed the results.
  • At both 2 and 4 weeks there was extensive vessel outgrowth, with branching vessels found up to the edge of the PLGA. Arterioles had formed, and healthy branching angiogenesis was seen coming from the loop. The cellular infiltrate was lying on the matrix and on the surface of the structure.
  • a capsule had formed on the proximal part of the flap only at 2 weeks. -Actin stain showed that this capsule contained myofibroblasts. At 4 weeks the capsule was thicker proximally, with more myofibroblasts and had extended to encompass the whole flap.
  • PLGA prepared by a fiber-spun method.
  • the vascular loop model described in Example 1 was used in this experiment.
  • the AV loop was placed within a round polycarbonate chamber (0.5 ml volume) filled with a PLGA disc (75% poly-L-lactic acid/25% polyglycolic acid) as the scaffold.
  • the PLGA scaffold was either manufactured by the salt leaching method described above or a fiber spun technique. Each group comprised five animals. After 4 weeks incubation and immediately before harvest heparinised India Ink was infused i.v. for 5 min. Tissue from the chamber was harvested, fixed in buffered 10% formalin, paraffin embedded, cut into 5 ⁇ m sections and stained with haematoxylin & eosin (H & E) for evaluation.
  • the salt-leached PLGA was less dense than the hard, dense consistency of the fiber-spun PLGA. This was evidenced by the subsequent cutting of the tissue/PLGA blocks for histological evaluation.
  • the salt-leached PLGA was brittle and prone to crumbling.
  • the fiber-spun PLGA was easy to section as it had a solid consistency and did not crumble. Histological examination showed a consistent pattern for all specimens in their respective groups.
  • the fiber-spun PLGA differed in character. The neovascularization and new tissue formation developed predominantly in a two dimensional plane.
  • tissue preferentially surrounded the PLGA discs and migrated towards the edge of the chamber. Tissue invaded the matrix at a much slower rate. Once the edge of disc was reached further thickening of new tissue grew around the disc but not completely engorging it after 4 weeks. Further modifications to the fibre-spun PLGA, such as increasing the pore size and decreasing the density (and therefore the hardness) may make this technique a viable alternative to the salt-leached PLGA preparation.
  • Example 6 Model system for vascularized tissue
  • the tissue chamber and graft system of the invention may be used as a model to examine the behaviour of vascularised tissue, through the use of an extracorporeal circulation machine to maintain the developing tissue in vitro during its generation.
  • the chamber contents are established as specified in Example 1.
  • the host's blood or suitable transfused blood (at least 90 ml) is taken and heparinised (up to 50 units/ml) .
  • the blood vessel ends are connected to silicone tubing and the blood is oxygenated via a renal dialysis filter.
  • the oxygenated blood is pumped through the tissue using conventional intensive care unit instrumentation adapted for this purpose, and maintained in vitro in this manner until the tissue/organ is mature.
  • blood samples are constantly monitored to assess the degree of coagulation and the maintenance of haemostasis.
  • tissue/organ generated is microsurgically replaced into the appropriate site in the host.
  • the next step in testing our model is to add stem cells to the system and see whether tissue is generated de novo.
  • the isolation, expansion and seeding of "stem cells" into the chamber is a huge area for research in itself and is still in its infancy.
  • Example 7 Assessment of hypoxia within the tissue growth chamber
  • AV shunt loops were created in anaesthetised male rats as previously described in Example 1.
  • Standard-sized chambers 0.5 ml volume
  • Chambers were filled with Matrigel, as described in Example 5, and seeded with immortal rat L6 myoblasts (1 x 10 6 cells / 0.5 ml Matrigel) distributed over the entire surface area. Chambers were then positioned in the groin of the rat.
  • Chambers were harvested at 3 days, 7 days, and 2 and 4 weeks incubation. At the time of exploration the animals were again anesthetised with sodium phenobaritone (30 mg/ml) and an assessment of anoxia was made by injection of nitroimidazole (60 g/kg, i.p.) 2 hours before the time of chamber harvest: Rats were sacrificed with a lethal dose of pentobarbitone sodium (3 ml of a 325 mg/ml solution) after harvesting the chambers. Specimens within the chambers were processed for histology and immunostaining with nitroimidazole antibody. Under these circumstances, the only cells which label are those which are hypoxic ( ⁇ 10 mm Hg) and which are proliferating.
  • hypoxia is a driving force of angiogenesis in the polycarbonate chamber particularly in the first week.
  • Those cells remote from the AV loop were undoubtedly hypoxic but were not proliferating.
  • the hypoxic, proliferating cells were located in the advancing edge of the new tissue, but by the end of week 4 the chamber was well oxygenated throughout and new tissue formation had slowed considerably. Studies such as this enable the researcher to invetigate how hypoxia can influence the growth of new tissue within the chamber.
  • Example 8 Isolated, cultured cells added to chambers in the rat AV loop model
  • Myoblasts were generated from this harvested tissue by collagenase digestion and culturing in Ham's F10 culture medium containing 20% fetal calf serum with 2 ng/ml of bFGF. Myoblasts were identified by desmin immunostaining. Fibroblasts were removed by serial subculturing, taking advantage of the fact that they adhere to plastic within half an hour whereas myoblasts adhere after that time. Enriched myoblasts (2-4 x 10 6 cells) were inserted into either (1) Matrigel alone (approximately 0.5 ml) or (2) Matrigel (approximately 0.15 ml) with PLGA making up the balance of the volume.
  • matrices were placed around an AV loop within a standard 0.5 ml chamber, as previously described. These constructs were incubated subcutaneously for either 2, 4, 6, 12 or 16 weeks. At the time of exploration, the rats were placed under general anaesthesia, and the tissue formed within the chamber (also known as the "flap") was removed. Approximately half of the tissue was frozen in isopentane and the other half fixed in formalin, and sectioned, prior to morphological, histological and immunohistochemical staining.
  • the chambers from six rats were examined at 2 weeks. There was a large amount of muscle in four of these; and of these, 3 contained identifiable desmin-positive myoblasts and evidence of myotube formation. The other two contained no desmin-positive tissue.
  • Group B - 6 weeks (n 9) Of the 9 rats in this group, 2 constructs contained muscle and myotubes, 4 flaps contained no identifiable muscle, and 3 rats died prematurely.
  • Group D - 16 weeks (n 5) No results for this group.
  • GFP green fluorescent protein
  • Bone marrow-derived stromal cells were harvested from rat femurs by flushing them with normal saline. These cells were then labelled and sorted on a FACS machine. The stromal cell subpopulation was expanded by culturing in ⁇ -MEM medium containing 20% fetal calf serum. The expanded cells were retrovirally transfected with Green Fluorescent Protein (GFP) and a neomycin plasmid to enable them to be tracked within our flap. When sufficient cells were available we placed them at a concentration of 2 x 10 6 per 0.5 ml Matrigel into our AV loop chamber model.
  • GFP Green Fluorescent Protein
  • Example 9 Pancreatic cells added to chambers in the rat AV loop model to form a transplantable pancreatic organoid All experiments were performed using inbred Sprague- Dawley rats.
  • Pancreatic tissue for transplantation was prepared by various methods:
  • the extracellular matrix used as a support for seeding the islet preparations were used in one of the following configurations :
  • Group 1 Old (400-500 g) inbred Sprague Dawley rats were used. "Ficoll islets" were placed in Matrigel. There were 3 recipient rats. We used a 2.5:1 (donor:recipient) ratio, and 10-17 days incubation.
  • Islets were kept in culture in Matrigel, with DMEM media changes twice weekly, in parallel with the above in vivo experiments to test the longevity of islets in culture. Insulin immunostaining was performed on several such cultures at one and two months with positive staining results.
  • blood samples 100 ⁇ l were taken from the loop artery and vein and systemic venous circulation, for measurement of insulin levels by radioimmunoassay for the rat isoform.
  • Chambers were harvested at the above time points, and tissues were preserved in Buffered Formal Saline and routine histological preparation, followed by paraffin embedding. Histological sections were subjected to routine (H&E) and immunostaining (for insulin and glucagon) .
  • Tissue in the chambers was divided into four parts and serial sections made. Large amounts of angiogenesis and collagen deposition were confirmed, in keeping with the original model. H&E staining demonstrated occasional islet persistence in all groups, but not in all flaps. Inflammatory infiltrates were present in most flaps, consisting mainly of lymphocytes. Ductal elements were observed in the Group 5 "filtered pancreas" chambers, although no confirmatory immunohistochemistry was performed. Insulin and glucagon immunohistochemistry demonstrated occasional positive staining, particularly for glucagon.
  • Example 10 Increasing the amount of tissue in the rat model through the use of larger chambers.
  • Rat Experiments The amount of tissue produced in the rat using the standard chamber model (-0.3 ml) is quite substantial in comparison with the animal's body size, and corresponds to a small "breast” or small “organ” within the body. In order to be able to reproduce this finding in the humans it is essential to test the limits of tissue production. This can be done firstly in the rat, through the use of larger volume chambers. Therefore, the aim of this study was to assess whether larger amounts of tissue could be grown over a longer period of time (4-8 weeks) inside larger chambers. In this fashion it is proposed that this method can be used to produce clinically useful amounts of new tissue which, if necessary, could be transferred on its own vascular pedicle to another part of the same individual.
  • the basic model of the arteriovenous (AV) shunt loop in an enclosed growth chamber has been described in detail in Example 1.
  • the AV shunt was placed within a dome-shaped chamber ( Figure 2) .
  • the chamber was made of polycarbonate, had a proximal opening for the pedicle and consisted of a base plate and a lid. It had a base diameter of 17 mm, a centre-of-base to top-of-dome distance of 1.3 mm and an internal volume of 1.9 ml.
  • the standard chamber described in previous studies (for instance Examples 1 and 2) had a volume of 0.5 ml.
  • the AV shunt was sandwiched between two custom-made disks of
  • PLGA which was used as a matrix to fill the chamber.
  • the PLGA was prepared according to the salt leaching method described by Patrick et al.(1999). Pore sizes between 300-420 nm and a porosity of 80-90% was achieved.
  • the disks were sterilised by four cycles of mechanical stirring for 30 minutes in 100% ethanol, then three times sterile, phosphate buffered saline, before use.
  • Weight and volume measurements All specimens harvested from the chambers were assessed for volume and weight. The volumes of the specimens, as measured by fluid displacement, was not statistically significant different from the measured weights. The total average weight (equivalent to volume) of the specimens decreased progressively in time. The total average weight ⁇ standard deviation (SD) of each group of specimens was 1.07 ⁇ 0.06, 1.03 ⁇ 0.06, 0.96 ⁇ 0.06, and 0.81 ⁇ 0.18 grams,, at 2, 4, 6 and 8 weeks, respectively. This resulted in a statistically significant decrease of specimen weight between time points apart 4 weeks or longer, which may be accounted for by the progressive gradual resorption of PLGA matrix.
  • SD standard deviation
  • the amount of PLGA and tissue in the specimen was studied to assess their involvement in the overall decrease in weight of the specimens. All specimens were point counted microscopically with the aid of a grid to determine the percentage of specimen taken up by PLGA or tissue. The decrease in specimen wet weight was attributed to resorption of PLGA. The total average weight of PLGA ⁇ SD at 2, 4, 6, and 8 weeks, respectively, was 0.89 ⁇ 0.07, 0.56 ⁇ 0.14, 0.34 ⁇ 0.07, and 0.20 ⁇ 0.09 g. On the other hand the newly formed tissue component of the specimen showed a progressive increase of weight in time.
  • the experimental model used was the basic AV shunt loop in an enclosed growth chamber, however the experimental animal was the New Zealand White rabbit.
  • Pre-operative analgesia was given in the form of carprofen (1.5 mg/kg, s.c).
  • New Zealand White rabbits (2.0 to 2.8 kg) were anaesthetised with i.v. pentobarbitone (30 mg/kg) and maintained in a face mask with halothane and oxygen (2.0 L/min) .
  • a graft of 4-6cm (rabbits) respectively was harvested from the left femoral vein, and used to create an AV shunt between the proximal ends of the divided right femoral artery and vein.
  • the AV shunt was placed within a dome-shaped chamber, in this case made of polyurethane, with the approximate dimensions 3.0 cm diameter, 2.0 cm high, with an opening for the vessel entry and egress (Figure 2) .
  • a dome-shaped chamber in this case made of polyurethane, with the approximate dimensions 3.0 cm diameter, 2.0 cm high, with an opening for the vessel entry and egress ( Figure 2) .
  • the anatomy of the rabbit permitted the use of an AV pedicle rather than an AV loop, because the small connecting vessels in the surrounding tissue of the pedicle made it a naturally occurring flow-through loop. In this latter example the effect of the AV blood flow was comparable but the operating time and postoperative pain was less. In the usual configuration this chamber had a plurality of small perforations in the chamber walls.
  • Subcutaneous fat in the groin region was used as a source of adipocytes and adipogenic precursor cells. (Zuk et al, 2001) .
  • the fat tissue was formed into a crude slurry by injection through an 18 gauge needle. These cells were donated by and implanted into the same rabbit .
  • the AV shunt loop or pedicle was placed within the chamber, which was filled with a 3-dimensional matrix made of a combination of PLGA which was machined to fit the chamber, Matrigel, Type 1 porcine skin collagen or a similar suitable composition, and the preadipocyte-rich fat tissue slurry.
  • the Matrigel was then allowed to gel.
  • the lid was closed and the chamber embedded beneath the inguinal skin. The wound closed with 4-0 nylon sutures.
  • the tissue in the chamber was removed and its wet weight recorded.
  • the tissue was also be suspended by a fine cotton suture thread and wholly immersed in a beaker of water on a balance.
  • the mass assuming a density of 1.00 g/ml, is the tissue volume.
  • Specimens were fixed in buffered formol saline (BFS), embedded in paraffin and stained with either H&E or Masson's Trichrome (a connective tissue stain) .
  • the volume of new tissue generated after 8 weeks growth was 10-11 ml (compared with a total volume of the chamber estimated to be 12 ml) .
  • the composition of the flap was adjudged to be a mixture of adipose and other connective tissue.
  • the shape was preserved when transferred under the nipple of the same male rabbit and the volume sufficient to enable the construction of a medium sized breast on this animal (see Figure 6) .
  • tissue thus produced was of a size and shape potentially suitable for breast reconstruction and similar applications. Flaps such as these with their associated patent blood vessels have the potential to be transferred to another part of the body for reconstructive purposes .
  • Example 11 A new model of vascularised tissue engineering in the mouse.
  • Stem cells are pluripotent cells that give rise to all tissues; they are highly durable and can therefore theoretically resist the initially hostile ischaemic environment of the chamber. This makes them attractive cells to seed in the chamber.
  • Stem cell biologists have cloned a wide variety of stem-cell sub-types in mice that can be seeded into the mouse model in order to attempt to generate specific tissue types.
  • mice There are also significant cost benefits in using mice. Purchase, housing and caring for mice is less expensive than for larger animals. Also there will be a reduction in the use of expensive laboratory consumables such as growth factors.
  • AVP arteriovenous pedicle
  • FTLP flow through loop pedicle
  • the polycarbonate chamber when used in the rat model, did not adversely affect the patency rate of the high-flow microsurgical arteriovenous loop. It was also tolerated well by these animals. However this material is hard and has sharp edges which was felt might affect the patency rate in the mouse due to the lower flow rate of the proposed vascular configurations and smaller diameter vessels in this animal. Therefore polycarbonate chambers were compared with softer silicone chambers in order to determine the most suitable material to use in the construct of the chamber.
  • the superficial epigastric (SE) vessels were dissected free of the surrounding tissue from their origin at the femoral vessels for a distance of approximately 1 cm to their entry into the groin fat pad.
  • SE superficial epigastric
  • the vessels course through the fat pad sending nutritional branches to the fat and glandular tissue around them. They then anastomose directly with an ilio- inguinal vessel (a direct branch of the infra-renal aorta) that pierces the abdominal wall at the lateral aspect of the inguinal ligament to enter the fat pad from the lateral side.
  • the entire fat pad is mobilised free of the skin and underlying muscle thus creating a space into which the chamber will alter be introduced.
  • the SE vessels have an arterial input and venous drainage from both sides which we felt would augment the long term patency rate in this model.
  • This is the first time that this vascular arrangement has been described in the mouse.
  • the first cm of the SE vessels (where they are free of the fat pad) is then encapsulated in a modified polycarbonate chamber that is split down one side and the appropriate extracellular matrix (Matrigel or PLGA) is inserted into the chamber.
  • the chamber is then sealed at the proximal end and along the lateral split using melted bone wax (Ethicon bone waxTM) taking care not to apply the heated wax directly to the vessels.
  • the seal is augmented by two 10/0 nylon microsutures placed at either end of the lateral split and the whole chamber is anchored to the underlying muscle near the origin of the SE vessels in order to prevent the pedicle from being dislodged during post-operative mobilisation.
  • a small amount of fatty tissue surrounding the vessels as they enter the fat pad is allowed to "plug" the distal end of the chamber.
  • This plug is then augmented with wax sealant and the whole construct is carefully placed in the groin so that it lies in the dissected space lateral to the femoral vessels.
  • the wounds were closed using a combination of buried interrupted horizontal mattress sutures and a running suture (both 6/0 silk) as these animals tend to gnaw at their wounds.
  • Matrigel is usually added as a liquid and allowed to gel in vivo. Some spillage may occur during infusion or during manipulation of the chamber. We also noted that the volume of the Matrigel declined by at least 50% over the first two weeks such that the specimen that was removed was actually smaller than that inserted.
  • the specimens were fixed in formalin and taken through graded alcohol solutions to absolute alcohol. They were then immersed in methyl salicylate and allowed to clear over 72 hours. This allows direct visualization of the vascular tree which has been perfused with India ink. All specimens were then examined as whole-mount preparations under microcater and vessel counts were performed. After this the specimens were processed for histological examination and embedded in wax. The wax blocks were then sectioned at 5 ⁇ m and stained with haematoxylin and eosin in a standard fashion. Vessel area density was estimated on all cleared specimens using a microcater which allowed visualization throughout the depth of these small tissue specimens. Three fields were randomly selected at 3 depth intervals of 500 ⁇ m and the vessel density was assessed with the aid of a stereometric grid.
  • the specimens were committed to histological processing.
  • the stained sections were morphologically assessed in terms of angiogenesis and the cellular characteristics of the newly generated tissue. Univariate analysis of the patency rates and vessel density was performed using the Student t-test. The patency rate was assessed for the two vascular configurations and for the different materials used in the make-up of the chamber.
  • the patency rate for the tied off arteriovenous pedicle was 21% versus 88% for the flow-through pedicle.
  • the patency rate in the polycarbonate chambers (excluding the tied off AV pedicle group) was 88% versus 97% in the silicone chambers.
  • the new vessels in the tied off AVP group were seen to be arising from outside the chamber and growing in along the thrombosed pedicle.
  • the vessel densities in the flow-through chambers were similar at 2, 4 and 6 weeks.
  • there was no difference in vessel density between PLGA and Matrigel Morphologically there was good angiogenesis in Matrigel® and PLGA but qualitatively it was better in the Matrigel®.
  • the new vessels seemed to be more numerous and occurred throughout the construct in the Matrigel®.
  • the angiogenesis in the PLGA was more to the periphery of the construct with fewer vessels in the central aspect probably due to the solid nature of this ECM.
  • the PLGA seemed to promote a predominately fibrous foreign-body type reaction. Fibroblasts are the predominant cell seen both peripherally where the matrix lay against the chamber wall and centrally within the substance of the matrix.
  • the Matrigel® group also showed a fibroblastic response at the ECM-chamber interface.
  • the central aspect of the Matrigel® shows the presence of fat in the chamber that has clearly migrated through the matrix and survived, presumably nourished by the newly generated vascular tree. This phenomenon has been reported before in non-encapsulated Matrigel® in mice using growth factors and pre-adipocytes. The presence of mature viable fat in the chamber suggests this model is capable of supporting the migration, maturation and possibly the reproduction of fat cells and their precursors.
  • the fat pad contains some mammary tissue and associated ducts, which are occasionally found in the distal part of the chamber where this tissue is used as a "plug" to seal the distal aperture.
  • the breast ductal/acinar tissue seemed to be growing into the Matrigel and in others there is clear morphological evidence of newly forming ductal/acinar tissue. This suggests that the chamber is capable of supporting the development of glandular tissue as well as fat. To our knowledge this has not been reported before.
  • pancreatic islets As well as this we have been successful in getting cultured adult pancreatic islets to survive and produce hormones at 2 and 10 weeks in wild type mice (C57BL6) . This effectively means that we have successfully grown functioning islet allograft in these animals which has not been achieved in other models of pancreatic transplantation. This means that the chamber may confer some immuno-privileged status to the cells that grow within it . This has therapeutic implications in that it may be possible to use unmatched allograft or even xenograft in the chamber with or without local immunosuppression or Sertoli cell co-culture as a treatment of Diabetes Mellitus.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Prostheses (AREA)

Abstract

L'invention porte sur un procédé de production d'un tissu vascularisé, ce procédé utilisant un pédoncule vasculaire renfermé dans une chambre et implanté chez un donneur. L'invention porte également sur une greffe de tissu vascularisé approprié pour être transplanté. L'invention porte en outre sur un procédé de réparation d'un tissu déficitaire par greffe d'un tissu vascularisé.
PCT/AU2001/001031 2000-08-21 2001-08-21 Greffe d'un tissu vascularisé WO2002015914A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP01962458A EP1335735A4 (fr) 2000-08-21 2001-08-21 Greffe d'un tissu vascularis
AU2001283687A AU2001283687B2 (en) 2000-08-21 2001-08-21 Vascularised tissue graft
KR10-2003-7002551A KR20030043937A (ko) 2000-08-21 2001-08-21 혈관분포된 조직 이식편
CA2419923A CA2419923C (fr) 2000-08-21 2001-08-21 Greffe d'un tissu vascularise
JP2002520835A JP2004505746A (ja) 2000-08-21 2001-08-21 血管化組織移植片
AU8368701A AU8368701A (en) 2000-08-21 2001-08-21 Vascularised tissue graft
NZ524234A NZ524234A (en) 2000-08-21 2001-08-21 Vascularised tissue graft
US10/362,243 US20040052768A1 (en) 2000-08-21 2001-08-21 Vascularised tissue graft
US10/888,436 US7998735B2 (en) 2000-08-21 2004-07-08 Vascularized tissue graft
US11/771,954 US20070299508A1 (en) 2000-08-21 2007-06-29 Vascularized tissue graft
US13/445,685 US20120209403A1 (en) 2000-08-21 2012-04-12 Vascularized tissue graft

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPQ9553 2000-08-21
AUPQ9553A AUPQ955300A0 (en) 2000-08-21 2000-08-21 Vascularised tissue graft
US25249700P 2000-11-22 2000-11-22
US60/252,497 2000-11-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10362243 A-371-Of-International 2001-08-21
US10/888,436 Continuation-In-Part US7998735B2 (en) 2000-08-21 2004-07-08 Vascularized tissue graft

Publications (1)

Publication Number Publication Date
WO2002015914A1 true WO2002015914A1 (fr) 2002-02-28

Family

ID=25646410

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2001/001031 WO2002015914A1 (fr) 2000-08-21 2001-08-21 Greffe d'un tissu vascularisé

Country Status (7)

Country Link
EP (1) EP1335735A4 (fr)
JP (1) JP2004505746A (fr)
KR (1) KR20030043937A (fr)
CN (1) CN1461220A (fr)
CA (1) CA2419923C (fr)
NZ (1) NZ524234A (fr)
WO (1) WO2002015914A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099784A1 (fr) * 2004-04-12 2005-10-27 Dai Nippon Printing Co., Ltd. Tissu artificiel et procédé servant à produire celui-ci
EP2598181A1 (fr) * 2010-07-31 2013-06-05 Cook Medical Technologies LLC Procédés et systèmes de génération d'une poche en tissu chez un patient
WO2015033337A1 (fr) * 2013-09-03 2015-03-12 Technion Research & Development Foundation Limited. Lambeau pour régénération tissulaire de novo
WO2023031167A1 (fr) * 2021-08-31 2023-03-09 Universität Heidelberg Implant périvasculaire

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009095579A (ja) * 2007-10-19 2009-05-07 Takahiro Otomo 豊胸法
EP3148601A1 (fr) * 2014-05-27 2017-04-05 Novahep AB Valve allogénique obtenue par génie génétique
EP2995278A1 (fr) * 2014-09-09 2016-03-16 Klinikum rechts der Isar der Technischen Universität München Implant médical/chirurgical
GB201510913D0 (en) * 2015-06-22 2015-08-05 Nat University Of Singapore And Agency For Science Technology And Res Vascularized tissue, skin or mucosa quivalent
CN104940999A (zh) * 2015-06-29 2015-09-30 苏州佑君环境科技有限公司 一种血管壁弹性基膜及其制备方法
US20180356398A1 (en) * 2017-06-09 2018-12-13 Fujifilm Corporation Living tissue model device, vascular wall model, vascular wall model device and method of evaluating test substance
CN107648669B (zh) * 2017-10-24 2020-11-17 武汉大学 构建血管化组织工程骨膜的方法
CN108753657A (zh) * 2017-11-01 2018-11-06 汪辉 一种缓释系统及其用途
CN112980690B (zh) * 2019-12-17 2022-10-21 华东数字医学工程研究院 Pdx模型孵育装置和抗肿瘤药物筛选方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008850A1 (fr) * 1991-10-30 1993-05-13 Massachusetts Institute Of Technology Implants polymeres prevascularises pour la transplantation d'organes
US5916554A (en) * 1992-07-29 1999-06-29 Washington University Use of pouch for implantation of living cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176874B1 (en) * 1993-10-18 2001-01-23 Masschusetts Institute Of Technology Vascularized tissue regeneration matrices formed by solid free form fabrication techniques
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008850A1 (fr) * 1991-10-30 1993-05-13 Massachusetts Institute Of Technology Implants polymeres prevascularises pour la transplantation d'organes
US5916554A (en) * 1992-07-29 1999-06-29 Washington University Use of pouch for implantation of living cells

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBMED [online] VOGELIN E., BREKKE J.H., JONES N.F.: "Heterotopic and orthotopic bone formation with a vascularized periosteal flap, a matrix and rh-BMP-2 (bone morphogenetic protein) in the rat model", XP002907153, accession no. Medline Database accession no. 11094515 *
GERMAIN M.A., TROTOUX J.: "(Prefabricated free transplants. Experimentation) Les transplants libres prefabriques. experimentation", ANNALES D'OTO-LARYNGOLOGIE ET DE CHIRURGIE CERVICO-FACIALE, vol. 106, no. 5, 1989, pages 351 - 353, XP002974046 *
LEE H.B., LEW D.H.: "De novo induction of island flap by using two silastic sheets: Part 1. Generation", PLASTIC AND RECONSTRUCTIVE SURGERY, vol. 104, no. 4, September 1999 (1999-09-01), pages 1023 - 1028, XP002974536 *
MACHENS H.-G. ET AL: "Biol. Matrices Tissue Reconstr.", 1998, SPRINGER VERLAG, BERLIN, GERMANY, article "Genetically modified fibroblasts induce angiogenesis in the rat epigastric island flap", pages: 53 - 59, XP002974059 *
MUND KIEFER GESICHTSCHIR., no. 4 SUPPL., September 2000 (2000-09-01), pages S454 - S458 *
See also references of EP1335735A4 *
VILJANEN V.V. ET AL: "Producing vascularized bone by heterotopic bone induction and guided tissue regeneration: a silicone membrane-isolated latissimus dorsi island flap in a rat model", JOURNAL OF RECONSTRUCTIVE MICROSURGERY, vol. 13, no. 3, April 1997 (1997-04-01), pages 207 - 214, XP002974045 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005099784A1 (fr) * 2004-04-12 2005-10-27 Dai Nippon Printing Co., Ltd. Tissu artificiel et procédé servant à produire celui-ci
EP2598181A1 (fr) * 2010-07-31 2013-06-05 Cook Medical Technologies LLC Procédés et systèmes de génération d'une poche en tissu chez un patient
EP2598181B1 (fr) * 2010-07-31 2021-04-21 Cook Medical Technologies LLC Poche de tissu collagène pour un dispositif médical implantable, et son procédé de fabrication
WO2015033337A1 (fr) * 2013-09-03 2015-03-12 Technion Research & Development Foundation Limited. Lambeau pour régénération tissulaire de novo
US11147899B2 (en) 2013-09-03 2021-10-19 Technion Research & Development Foundation Limited Flap for de-novo tissue regeneration
WO2023031167A1 (fr) * 2021-08-31 2023-03-09 Universität Heidelberg Implant périvasculaire

Also Published As

Publication number Publication date
CN1461220A (zh) 2003-12-10
CA2419923A1 (fr) 2002-02-28
KR20030043937A (ko) 2003-06-02
CA2419923C (fr) 2013-03-12
EP1335735A4 (fr) 2007-05-16
NZ524234A (en) 2004-10-29
EP1335735A1 (fr) 2003-08-20
JP2004505746A (ja) 2004-02-26

Similar Documents

Publication Publication Date Title
US20040052768A1 (en) Vascularised tissue graft
US7998735B2 (en) Vascularized tissue graft
CA2419923C (fr) Greffe d'un tissu vascularise
US20180256643A1 (en) Method of ex vivo cellular growth
AU2001283687B2 (en) Vascularised tissue graft
AU2001283687A1 (en) Vascularised tissue graft
US10016460B2 (en) Method of inducing cellular growth and materials for use therewith
JF Patzer et al. Clinical safety evaluation of excorp medical, inc. Bioartificial liver support system (BLSS)
Sodian et al. Application of stereolithography for scaffold fabrication for tissue engineering of heart valves
Koball et al. REMOVAL OF ALBUMIN BOUND TOXINS WITH THE MARSSYSTEM SHOWS PROTECTIVE EFFECTS ON HEPATOCYTES
Jockenhoevel et al. CARDIOVASCULAR TISSUE ENGINEERING: A NEW LAMINAR FLOW CHAMBER FOR: IN VITRO: IMPROVEMENT OF MECHANICAL TISSUE PROPERTIES
Livingston et al. Osteogenic activity of human mesenchymal stem cells in vivo on calcium phosphate ceramics
Donini et al. TEMPORARY NEUROLOGICAL IMPROVEMENT AFTER BIOARTIFICIAL LIVER TREATMENT FOR ACUTE ON CHRONIC LIVER FAILURE
Peszynski et al. REMOVAL OF ALBUMIN BOUND DRUGS IN ALBUMIN DIALYSIS (MARS)-A NEW LIVER SUPPORT SYSTEM
Jockenhoevel et al. TISSUE ENGINEERING: EVALUTATION OF DIFFERENT BIODEGRADABLE SCAFFOLDS
Klammt et al. Impact of artificial liver support with albumin dialysis (MARS) on laboratory findings
Nasseri et al. IMPACT OF CULTURE CONDITIONS ON PROLIFERATION AND SURVIVAL OF FETAL CARDIOMYOCYTES
Suh et al. STUDY ON REPLACEMENT OF TRACHEAL DEFECT WITH AUTOGENOUS MUCOSA-LINED TRACHEAL PROSTHESIS MADE FROM POLYPROPHYLENE MESH
Shomura et al. INDUCED CELL DEATH FOLLOWED BY LYOPHILIZATION AS AN ALTERNATIVE METHOD FOR AORTIC VALVE HOMOGRAFT PRESERVATION
Trumble et al. CHRONIC STIMULATION PROMOTES REMODELING OF THE EXTRACELLULAR MATRIX IN SKELETAL MUSCLE
Ehashi et al. ONCOSTATIN M REMARKABLY STIMULATES CELL PROLIFERATION AND HEPATIC FUNCTIONS OF THE FETAL LIVER CELLS CULTURED ON A THREE-DIMENTIONAL POLYMER SCAFFOLD
Aung et al. CHONDROINDUCTION OF MOUSE MESENCHYMAL STEM CELLS IN A THREE-DIMENSIONAL POROUS POLYVINYL FORMAL RESIN
Zdrahala et al. IN VIVO TISSUE ENGINEERING: A BRIDGE BETWEEN MECHANISTIC AND GENETIC MEDICINE
Muehlbauer EVALUATION OF IN-VIVO TRANSPORT KINETICS OF SUBCUTANEOUSLY IMPLANTED DIFFUSION CHAMBERS
Peter et al. Predifferentiation of human MSCs in vitro leads to osteogenesis in vivo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001283687

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 524234

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002520835

Country of ref document: JP

Ref document number: 2419923

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037002551

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003/02205

Country of ref document: ZA

Ref document number: 200302205

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 01816000X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001962458

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037002551

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001962458

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10362243

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 524234

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524234

Country of ref document: NZ